What question did this study set out to answer?

To evaluate how mavacamten therapy affects myocardial systolic function using advanced imaging techniques.

March 7, 2026Open Access

Effect of Mavacamten Therapy on Myocardial Systolic Function Assessed by 3D Echocardiography

Resultado clave

Mavacamten therapy causes a decline in LVEF due to regional hypokinesia rather than global dysfunction in obstructive HCM, according to 3D echocardiography.

Puntos clave

To evaluate how mavacamten therapy affects myocardial systolic function using advanced imaging techniques.
Assessed myocardial function through 3D echocardiography
Examined LVEF (Left Ventricular Ejection Fraction) during mavacamten therapy
Focused on measuring regional hypokinesia instead of global dysfunction
LVEF decline occurs regionally, indicating specific areas of reduced heart function
Three-dimensional imaging provides clearer insights into treatment effects
Mavacamten therapy reveals hypokinesia without indicating global heart failure

PICO estructurado

Does mavacamten therapy cause regional or global myocardial systolic dysfunction in patients with oHCM?

Población

Patients with obstructive hypertrophic cardiomyopathy (oHCM)

Intervención

Mavacamten

Resultado

Myocardial systolic function (LVEF decline) assessed by 3D echocardiographysurrogate

3D echocardiography reveals that LVEF decline from mavacamten in oHCM is due to regional hypokinesia rather than global dysfunction.

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

Mavacamten-induced LVEF decline reflects regional hypokinesia, not global dysfunction. Three-dimensional imaging enhances understanding of treatment response in oHCM.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo